HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02142 HBM HOLDINGS-B

Not Yet Opened 07-02 16:08:21

10.790

+0.350

+3.35%

High11.060	Low10.650	Vol3.32M
Open10.750	D1 Closing10.440	Amplitude3.93%
Mkt Cap9.37B	Tradable Cap9.37B	Total Shares868.00M
T/O36.02M	T/O Rate0.38%	Tradable Shares868.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"HBM HOLDINGS-B","latestPrice":10.79,"timestamp":1782979701004,"preClose":10.44,"halted":0,"volume":3319000,"delay":0,"changeRate":0.03352490421455936,"floatShares":868000000,"shares":868000000,"eps":0.11,"marketStatus":"Not Yet Opened","change":0.35,"latestTime":"07-02 16:08:21","open":10.75,"high":11.06,"low":10.65,"amount":36015899,"amplitude":0.039272,"askPrice":10.79,"askSize":6000,"bidPrice":10.78,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.856171,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1783042200000},"marketStatusCode":0,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":10.44,"openAndCloseTimeList":[[1782955800000,1782964800000],[1782968400000,1782979200000]],"volumeRatio":0.68919,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142/tweets","defaultTab":"tweets","newsList":[{"id":"2648522004","title":"Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-class Single-domain Antibody-based Bbb-crossing Technology for CNS Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2648522004","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648522004?lang=en_us&edition=fundamental","pubTime":"2026-07-02 08:05","pubTimestamp":1782950754,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nTUA6LHHSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647374356","title":"Shanghai Court Dismisses HBM Subsidiary's Patent Infringement Claim Against Biocytogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2647374356","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647374356?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:46","pubTimestamp":1782737188,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals (Beijing) (HKG:2315) scored a legal win in China after a court dismissed a claim made by HBM (HKG:2142) subsidiary Harbour Antibodies.Specifically, the Shanghai Intellectual","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAM","DRAM","02142","BK1161","02315","BK1574","BK1583","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647916344","title":"Harbour Biomed Appoints Lloyd Klickstein Scientific Advisor for Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2647916344","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647916344?lang=en_us&edition=fundamental","pubTime":"2026-06-29 09:28","pubTimestamp":1782696496,"startTime":"0","endTime":"0","summary":"Harbour BioMed appoints Lloyd Klickstein scientific advisor for immunologyHBM Holdings appointed Lloyd Klickstein as scientific advisor for immunology on June 28, 2026.Klickstein is CEO of Koslapp The","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDLbz98kH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115452403","title":"HBM Holdings Annual Meeting: All Eight Resolutions Secure Strong Shareholder Support","url":"https://stock-news.laohu8.com/highlight/detail?id=1115452403","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115452403?lang=en_us&edition=fundamental","pubTime":"2026-06-25 22:45","pubTimestamp":1782398700,"startTime":"0","endTime":"0","summary":"HBM Holdings Limited reported that every agenda item at its 25 June 2026 Annual General Meeting passed with wide margins, confirming board stability and refreshed corporate mandates. Key voting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144425345","title":"HBM HOLDINGS-B Shares Surge on AI Drug Discovery Venture Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1144425345","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144425345?lang=en_us&edition=fundamental","pubTime":"2026-06-17 10:48","pubTimestamp":1781664505,"startTime":"0","endTime":"0","summary":"Shares of HBM HOLDINGS-B (02142) have risen more than 5%. At the time of writing, the stock is up 5.34% to HK$10.66, with a turnover of HK$11.05 million. The increase follows a recent company...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","CHAT","02142","BK1574","BK4588","BK1161","BK1583","BK4585","AIPO","AGIX","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171995009","title":"HBM Holdings and Baidu's Biotech Arm Forge AI Drug Discovery Alliance, Launching MegaStream TechBio","url":"https://stock-news.laohu8.com/highlight/detail?id=1171995009","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171995009?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:20","pubTimestamp":1781526037,"startTime":"0","endTime":"0","summary":"HBM Holdings-B (HKEX: 02142) has announced a comprehensive, long-term strategic partnership with Baidu's biotech subsidiary, Baitu Shengke. The collaboration will focus on AI-driven discovery and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","CHAT","BK1161","BK1574","AGIX","BK1583","AIPO","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203523","title":"HBM Holdings partners with BioMap to co-found AI drug R&D venture MegaStream TechBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203523","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203523?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:08","pubTimestamp":1781525286,"startTime":"0","endTime":"0","summary":"HBM Holdings launched a strategic partnership with BioMap to co-build AI drug developer MegaStream TechBio for global markets.MegaStream will combine proprietary datasets, bespoke foundation models, integrated discovery platforms to advance complex biologic pipelines.HBM will contribute its fully human antibody platform, target biology capabilities, clinical development experience.BioMap will provide AI technology, model engineering support, automated R&D capabilities to accelerate pipeline progress.Founders expect upfront payments, milestone payments, profit-sharing from MegaStream programs; initial pipeline to include prior joint AI projects.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL7FGbB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643566203","title":"Hbm - Co and Biomap to Jointly Initiate Megastream Techbio","url":"https://stock-news.laohu8.com/highlight/detail?id=2643566203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643566203?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:07","pubTimestamp":1781525220,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N01Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643033702","title":"Hbm - Co and Biomap Enter Global Strategic Partnership for AI-Driven Biologics","url":"https://stock-news.laohu8.com/highlight/detail?id=2643033702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643033702?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:07","pubTimestamp":1781525220,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N01Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112124731","title":"HBM Holdings-B Prevails in Patent Infringement Case Against Amgen, Awarded Approximately $20.2 Million with Potential for Triple Damages","url":"https://stock-news.laohu8.com/highlight/detail?id=1112124731","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112124731?lang=en_us&edition=fundamental","pubTime":"2026-06-15 08:47","pubTimestamp":1781484475,"startTime":"0","endTime":"0","summary":"In a recent legal development, HBM Holdings-B (ASX: 02142) has announced a favorable jury verdict in a patent infringement lawsuit. The jury in the U.S. District Court for the District of Delaware...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4139","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","BK4534","LU0868494617.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","LU2112291526.USD","IE0002141913.USD","IE0009355771.USD","LU1983299246.USD","LU2468319806.SGD","BK1574","LU1023059063.AUD","LU0889565916.HKD","BK4588","BK4585","AMGN","LU0289739699.SGD","BK4566","LU2242646821.SGD","LU0058720904.USD","BK1161","LU1061106388.HKD","IE00B2B36J28.USD","02142","LU2089984988.USD","BK4533","BK1583","LU2242652126.USD","SG9999001440.SGD","BK4599","LU0122379950.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643280482","title":"Harbour Biomed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=2643280482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643280482?lang=en_us&edition=fundamental","pubTime":"2026-06-15 08:02","pubTimestamp":1781481734,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3HC08Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228063","title":"HBM Holdings wins US patent jury verdict against Amgen, awarded USD 20.2 million damages","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228063","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228063?lang=en_us&edition=fundamental","pubTime":"2026-06-15 08:00","pubTimestamp":1781481630,"startTime":"0","endTime":"0","summary":"A Delaware federal jury found Amgen infringed patents tied to HBM Holdings’ Harbour Antibodies unit’s antibody-discovery platform.Verdict included a finding of willful infringement. The jury also upheld the patents’ validity.Damages awarded totaled USD 20.2 million, matching the full amount sought.Willfulness finding allows a request for enhanced damages up to triple, implying potential total damages of about USD 60.6 million.The case stems from a patent infringement lawsuit filed in 2021 against Amgen and its unit Teneobio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  ,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL61mlXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU1983299246.USD","SG9999001440.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0109394709.USD","LU0122379950.USD","BK4139","IE00BFTCPJ56.SGD","BK1583","LU0289739699.SGD","IE0009355771.USD","LU2468319806.SGD","LU2242652126.USD","LU1571399168.USD","BK1161","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4585","IE00B2B36J28.USD","LU0889565916.HKD","LU2242646821.SGD","LU2089984988.USD","LU1061106388.HKD","BK1574","BK4533","LU0320765992.SGD","BK4581","BK4534","BK4588","IE0002141913.USD","02142","LU1023059063.AUD","LU2112291526.USD","BK4566","AMGN","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228056","title":"Hbm - Jury Returns Verdict in Favor of Harbour Antibodies Against Amgen in U.S. Patent Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228056?lang=en_us&edition=fundamental","pubTime":"2026-06-15 08:00","pubTimestamp":1781481624,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42K0LF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228051","title":"Hbm Holdings - Jury Verdict in U.S. Patent Infringement Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228051?lang=en_us&edition=fundamental","pubTime":"2026-06-15 08:00","pubTimestamp":1781481624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42K0LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228049","title":"Hbm Holdings - IF Such Enhanced Damages Are Granted in Full, Award Could Increase to up to Approximately US$60.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228049?lang=en_us&edition=fundamental","pubTime":"2026-06-15 08:00","pubTimestamp":1781481624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42K0LF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228043","title":"Hbm Holdings - Harbour Antibodies Is Entitled to Damages of US$20.2 Mln Being Full Amount Requested at Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228043?lang=en_us&edition=fundamental","pubTime":"2026-06-15 08:00","pubTimestamp":1781481624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42K0LF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643219713","title":"HBM Holdings (SEHK:2142) Stock Valuation After New IND Milestone For Cancer Antibody HBM7004","url":"https://stock-news.laohu8.com/highlight/detail?id=2643219713","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643219713?lang=en_us&edition=fundamental","pubTime":"2026-06-13 11:28","pubTimestamp":1781321337,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is back in focus after China’s National Medical Products Administration accepted its investigational new drug filing for HBM7004, a bispecific antibody for advanced solid tumors, following earlier U.S. FDA clearance.\nSee our latest analysis for HBM Holdings.\nDespite the positive regulatory news, the stock’s recent momentum has cooled, with a 30 day share price return down 21.58% and the year to date share price return down 16.97%. This comes even as the 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-stock-valuation-after-new-ind-mileston","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-stock-valuation-after-new-ind-mileston","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4168","DRAM","IND","BK1161","BK4588","DCF","HBM","BK1583","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643523216","title":"Amgen owes $20.2 million in antibody patent lawsuit, US jury says","url":"https://stock-news.laohu8.com/highlight/detail?id=2643523216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643523216?lang=en_us&edition=fundamental","pubTime":"2026-06-13 08:18","pubTimestamp":1781309906,"startTime":"0","endTime":"0","summary":"UPDATE 1-Amgen owes $20.2 million in antibody patent lawsuit, US jury saysAdds Amgen comment, lack of response from Harbour, see last two bulleted itemsBy Blake Brittain and David ThomasJune 12  - Amgen AMGN.O subsidiary Teneobio must pay biotech company Harbour Antibodies $20.2 million in damages for infringing a patent related to antibodies used in biologic drugs, a federal jury in Delaware said on Friday. The jury agreed with Harbour that Teneobio's UniRat platform violated Harbour's patent rights in technology for using genetically engineered mice to produce antibodies.Harbour's Harbour Mice are used to create antibodies for the research, development and production of biologic drugs.Biologics are made from biological cells, unlike traditional pharmaceuticals, and are among the most complex and expensive drugs on the market.Harbour, a Dutch subsidiary of China-based Harbour BioMed, sued Teneobio in 2021, arguing that Teneobio's UniRat system for genetically engineering rats mimicked","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260613:nL6N42K1AM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0122379950.USD","LU2242652126.USD","AMGN","BK4588","LU2468319806.SGD","LU0889565916.HKD","LU1023059063.AUD","SG9999001440.SGD","IE00BJJMRZ35.SGD","BK4534","BK4566","LU1571399168.USD","BK1574","LU1057294990.SGD","BK4581","02142","IE0002141913.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU0320765992.SGD","BK1161","LU0058720904.USD","BK4533","LU0109394709.USD","LU1061106388.HKD","BK4599","IE0009355771.USD","LU2112291526.USD","IE00B4R5TH58.HKD","BK4585","IE00B2B36J28.USD","LU1983299246.USD","BK1583","IE00BJT1NW94.SGD","LU2242646821.SGD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642825349","title":"Harbour BioMed appoints Sana Biotechnology CSO Dhavalkumar Patel as scientific advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2642825349","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642825349?lang=en_us&edition=fundamental","pubTime":"2026-06-12 09:19","pubTimestamp":1781227194,"startTime":"0","endTime":"0","summary":"HBM Holdings said Harbour BioMed appointed Dhavalkumar Patel as a scientific advisor on June 11, 2026.Patel is executive vice president, chief scientific officer at Sana Biotechnology.He previously served as executive vice president, chief scientific officer at UCB.Earlier roles include head of research for NIBR Europe at Novartis, following academic leadership posts at UNC Chapel Hill, Duke University.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL1Yrlqg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","BK1574","SANA","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642253418","title":"Press Release: Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2642253418","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642253418?lang=en_us&edition=fundamental","pubTime":"2026-06-12 09:19","pubTimestamp":1781227140,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced the appointment of Dr. Dhavalkumar Patel as Scientific Advisor.Dr. Patel brings an outstanding track record of therapeutic innovation spanning over two decades in industry and academia. He is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology.\"We are thrilled to welcome Dr. Patel to our Scientific Advisory Board,\" said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. \"His outstanding combination of deep immunological science, proven drug development success, and board-level strategic insight will be a tremendous asset to us. We look forward to his guidance as we continue to build a leading immunology pipeline.\". \"I am honored to join Harbour BioMed as a Scientific ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","BK4232","R","03160","BK4022","BK4555","BK4588","BK4585","TM","BK4604","BK4099","02142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0048},{"period":"1month","weight":-0.1069},{"period":"3month","weight":-0.2643},{"period":"6month","weight":-0.1414},{"period":"1year","weight":0.2311},{"period":"ytd","weight":-0.1414}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.4,"avgChangeRate":0.030357},{"month":8,"riseRate":0.2,"avgChangeRate":0.005624},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"HBM HOLDINGS-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HBM HOLDINGS-B(02142) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HBM HOLDINGS-B,02142,HBM HOLDINGS-B股票,HBM HOLDINGS-B股票老虎,HBM HOLDINGS-B股票老虎国际,HBM HOLDINGS-B行情,HBM HOLDINGS-B股票行情,HBM HOLDINGS-B股价,HBM HOLDINGS-B股市,HBM HOLDINGS-B股票价格,HBM HOLDINGS-B股票交易,HBM HOLDINGS-B股票购买,HBM HOLDINGS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HBM HOLDINGS-B(02142) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}